CRISPR-based gene therapy for huntington's disease: current advances and future prospects

Area of Science:

• Neuroscience
• Genetics
• Biotechnology

Background:

• Huntington's Disease (HD) is a neurodegenerative disorder caused by expanded CAG repeats in the HTT gene, leading to toxic mutant huntingtin (mHTT) protein.
• Current HD therapies have limitations in addressing the disease's genetic origin.

Purpose of the Study:

• To review CRISPR-Cas9 based therapeutic strategies for Huntington's Disease.
• To explore the mechanisms, efficacy, and challenges of gene editing for HD treatment.

Main Methods:

• Review of preclinical studies using CRISPR-Cas9 in animal models and human induced pluripotent stem cells (iPSCs).
• Analysis of various CRISPR-Cas9 mechanisms: repeat excision, allele-specific targeting, and epigenome editing.
• Evaluation of viral and non-viral delivery systems for CRISPR-Cas9 therapeutics.

Main Results:

• Preclinical studies demonstrate the efficacy of CRISPR-Cas9 strategies in reducing mHTT and correcting HD-related pathology.
• Delivery methods are crucial for optimizing therapeutic outcomes and minimizing adverse effects like off-target mutations and immune responses.
• Ethical and safety considerations, including precision and long-term impacts, are critical for clinical translation.

Conclusions:

• CRISPR-Cas9 technology offers a transformative approach to treating Huntington's Disease by targeting its genetic basis.
• Advancements in gene editing and delivery systems are paving the way for potential clinical applications in HD and other neurodegenerative diseases.